Purine inhibitors of fructose-1,6-bisphosphatase

Details Purine inhibitors of fructose-1,6-bisphosphatase Purine inhibitors of fructose-1,6-bisphosphatase

2007-10-23

2007-10-23

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

Reexamination Certificate

active

11101807

ABSTRACT:
Novel purine compounds of Formula 1, pharmaceutically acceptable prodrugs and salts thereof, and their use as fructose 1,6-bisphosphatase inhibitors.

REFERENCES:
patent: 3931206 (1976-01-01), Bowler et al.
patent: 4000305 (1976-12-01), Bowler et al.
patent: 4278791 (1981-07-01), Botta et al.
patent: 4939130 (1990-07-01), Jaeggi et al.
patent: 4968790 (1990-11-01), DeVries et al.
patent: 5021443 (1991-06-01), Bru-Magniez et al.
patent: 5124319 (1992-06-01), Baudy et al.
patent: 5294608 (1994-03-01), Lang et al.
patent: 5376665 (1994-12-01), Miyata et al.
patent: 5395826 (1995-03-01), Naumann et al.
patent: 5414088 (1995-05-01), Von Der Saal et al.
patent: 5480874 (1996-01-01), Shoji et al.
patent: 5498617 (1996-03-01), Naumann et al.
patent: 5519138 (1996-05-01), Ries et al.
patent: 5658889 (1997-08-01), Gruber et al.
patent: 5661174 (1997-08-01), Naumann et al.
patent: 5728704 (1998-03-01), Mylari et al.
patent: 5958904 (1999-09-01), Cordi et al.
patent: 5985856 (1999-11-01), Stella et al.
patent: 6054587 (2000-04-01), Reddy et al.
patent: 6110903 (2000-08-01), Kasibhatla et al.
patent: 6284748 (2001-09-01), Dang et al.
patent: 6294672 (2001-09-01), Reddy et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6399782 (2002-06-01), Kasibhatla et al.
patent: 6489476 (2002-12-01), Dang et al.
patent: 6756360 (2004-06-01), Erion et al.
patent: 6919322 (2005-07-01), Bookser et al.
patent: 6965033 (2005-11-01), Jiang et al.
patent: 6967193 (2005-11-01), Dang et al.
patent: 2003/0073728 (2003-04-01), van Poelje et al.
patent: 2004/0058892 (2004-03-01), Dang et al.
patent: 2004/0167178 (2004-08-01), Erion et al.
patent: 2005/0004077 (2005-01-01), Jiang et al.
patent: 2005/0176684 (2005-08-01), Bookser et al.
patent: 1328383 (1993-11-01), None
patent: 28 55 659 (1980-07-01), None
patent: 0 012 909 (1980-07-01), None
patent: 0 73 525 (1983-03-01), None
patent: 0 117 429 (1984-09-01), None
patent: 0 354 322 (1990-02-01), None
patent: 0 354 806 (1990-02-01), None
patent: 0 427 799 (1991-05-01), None
patent: 0 449 196 (1991-10-01), None
patent: 0 604 657 (1994-07-01), None
patent: 0 620 227 (1994-10-01), None
patent: 0 632 048 (1995-01-01), None
patent: 0 753 525 (1997-01-01), None
patent: 51105093 (1976-09-01), None
patent: 52023094 (1977-02-01), None
patent: 53044591 (1978-04-01), None
patent: 05-097883 (1993-04-01), None
patent: WO90/10636 (1990-09-01), None
patent: WO92/13864 (1992-08-01), None
patent: WO94/07867 (1994-04-01), None
patent: WO94/20508 (1994-09-01), None
patent: WO94/22864 (1994-10-01), None
patent: WO96/21644 (1996-07-01), None
patent: WO98/39342 (1998-09-01), None
patent: WO98/39343 (1998-09-01), None
patent: WO99/45016 (1999-09-01), None
patent: WO99/47549 (1999-09-01), None
patent: WO 00/14095 (2000-03-01), None
patent: WO 00/27401 (2000-05-01), None
patent: WO 00/38666 (2000-07-01), None
patent: WO 01/47935 (2001-07-01), None
patent: WO 01/52825 (2001-07-01), None
patent: WO 01/66553 (2001-09-01), None
patent: WO 02/03978 (2002-01-01), None
patent: WO 2006/023515 (2006-03-01), None
Azen, S.P., et al., “TRIPOD (TRoglitazone In the Prevention of Diabetes): A Randomized, Placebo-Controlled Trial of Troglitazone in Women with Prior Gestational Diabetes Mellitus,”Controlled Clinical Trials, vol. 19, Issue 2, pp. 217-231, Elsevier B.V. (Apr. 1998).
Chiasson, J.-L., et al., “Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data,”Diabetologia, 47: 969-975, Springer-Verlag (2004).
Delorme, S., et al., “Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus,”Current Opinion in Pharmacology, 5:184-189, Elsevier (2005).
Dickson, J.K. et al., “Orally Active Squalene Synthase Inhibitors: Bis((acyloxy)alkly) Prodrugs of the α-Phosphonosulfonic Acid Moiety”J. Med. Chem. 39: 661-664 American Chemical Society (1996).
Egron, D. et al., “Synthesis and Anti-HIV Activity of SomeS-Acyl-2-Thioethyl (Sate) Phosphoramidate Derivatives of 3′-Azido-2′,3′Dideoxythymidine”Nucleosides&Nucleotides18(4&5): 981-982 Marcel Dekker, Inc. (1999).
Erion, M.D. et al., “Computer-Assisted Scanning of Ligand Interactions: Analysis of the Fructose 1,6-Bisphosphatase-AMP Complex Using Free Energy Calculations”J. Am. Chem. Soc. 122: 6114-6115 American Chemical Society (2000).
Erion, M.D. and Reddy, M.R. “Ligand Interaction Scanning Using Free Energy Calculations”Free Energy Calculations in Rational Drug Design, Chapter 11, 225-241 Springer-Verlag (2001).
Erion, M.D. et al., “MB06322 (CS-917): A Potent and Selective Inhibitor of Fructose 1,6-Bisphosphatase for Controlling Gluconeogenesis in Type 2 Diabetes”PNAS102(22): 7970-7975 (May 31, 2005).
Fisher, J.S. et al., “Glucose transport rate and glycogen synthase activity both limit skeletal muscle glycogen accumulation,”The American Journal of Physiology Endocrinol. Metab., vol. 282, pp. E1214-E1221 American Physiological Society (Jun. 2002).
Fujiwara, T. et al., “Suppression of Hepatic Gluconeogenesis in Long-Term Troglitazone Treated Diabetic KK and C57BL/KsJ-db/db Mice”Metabolism44(4): 486-490 (Apr. 1995).
Gidh-Jain, M. et al., “The Allosteric Site of Human Liver Fructose-1,6-Bisphosphatase”Journal of Biological Chemistry269(44): 27732-27738 The American Society for Biochemistry and Molecular Biology, Inc. (1994).
Holman, R.R. et al., “Assessing the potential for α-glucosidase inhibitors in prediabetic states,”Diabetes Research and Clinical Practice, vol. 40, Supp. 1, pp. 21-25, Elsevier Ireland Ltd. (Jul. 1998).
Howard, G. et al., “Insulin Sensitivity and Atherosclerosis”Circulation93(10): 1809-1817 (May 15, 1996).
Hulley, S. et al., “Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women,”J. of Am. Medical Assoc., vol. 280, No. 7, pp. 605-613 (Aug. 19, 1998).
Inzucchi, S.E. et al., “Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus”N.E. Journal of Medicine338(13): 867-872 Massachusetts Medical Society (Mar. 26, 1998).
Link, J.T. et al., “Pharmacological regulation of hepatic glucose production,”Curr. Opin. Investig. Drugs4(4):421-429 (Apr. 2003).
Maggs, D.G. et al., “Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus”Annals of Internal Medicine128(3): 176-185 American College of Physicians (Feb. 1, 1998).
Okuno, A. et al., “CS-917, a Fructose 1,6-Bisphosphatase (FBPase) Inhibitor, Suppresses Gluconeogenesis In Vitro and In Vivo by a Different Mechanism than Metformin” poster presented at The American Diabetes Association 66thScientific Session, Washington, DC (Jun. 2006).
Pickavance, L. et al., “The Development of Overt Diabetes in Young Zucker Diabetic Fatty (ZDF) Rats and the Effects of Chronic MCC-555 Treatment”British Journal of Pharmacology, 125: 767-770 Stockton Press (1998).
Potter, S.C. et al., “Effect of MB06322, a Potent and Selective Inhibitor of Fructose 1,6-Bisphosphatase, on Gluconeogenesis in the ZDF Rat as Assessed by the Deuterated Water Technique”DIAEAZ52(5): A364, Journal of the American Diabetes Association Abstract No. 1516-P, American Diabetes Association (Jun. 2004).
Potter, S.C., “Evidence Implicating Gluconeogenesis Inhibition as the Mechanism by Which MB06322 Lowers Blood Glucose In Vivo”DIAEAZ52(2): A364, Journal of the American Diabetes Association Abstract No. 1517-P, American Diabetes Association (Jun. 2004).
Prisant, L.M., “Preventing Type II Mellitus,”J. Clin. Pharmacol., 44:406-413, American College of Clinical Pharmacology (2004).
Reddy, M.R. and Erion, M.D. “Computer Aided Drug Design Strategies Used in the Disc

Affiliated with

Also associated with

Rating

Purine inhibitors of fructose-1,6-bisphosphatase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Purine inhibitors of fructose-1,6-bisphosphatase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine inhibitors of fructose-1,6-bisphosphatase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3855788